{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000155","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.831489+00:00","generated_at":"2026-05-28T03:42:31.391878+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Aprea Therapeutics reports Dec 31, 2024 cash balance of $22.8M","bullets":["Cash and cash equivalents of $22.8M as of December 31, 2024 (preliminary, unaudited).","Disclosed via corporate presentation posted to company website on January 13, 2025.","Balance subject to completion of fiscal 2024 year-end financial statements.","No other financial results or guidance provided in the presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000155","json":"https://secwatch.observer/filing/0001558370-25-000155.json","markdown":"https://secwatch.observer/filing/0001558370-25-000155.md","text":"https://secwatch.observer/filing/0001558370-25-000155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025000155/0001558370-25-000155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025000155/apre-20250113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:42:31.391878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}